Supplementary Table S2 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an <i>IDH1</i> Mutation

Authors

Xin Wang
Sarah E. Dorff (ORCID: https://orcid.org/0009-0004-0762-5844)
R. Angelo de Claro (ORCID: https://orcid.org/0000-0001-8362-1977)
Jonathon Vallejo (ORCID: https://orcid.org/0000-0002-9700-4037)
Kelly J. Norsworthy (ORCID: https://orcid.org/0000-0002-8462-9994)
Richard Pazdur (ORCID: https://orcid.org/0000-0002-4771-9923)
Jiang Liu (ORCID: https://orcid.org/0000-0002-5755-3904)
Marc Robert Theoret (ORCID: https://orcid.org/0000-0003-4973-5297)
Ólanrewaju O. Okusanya (ORCID: https://orcid.org/0000-0002-4134-7882)
Ashley Woods (ORCID: https://orcid.org/0009-0001-4878-5463)
Dianne Pulte (ORCID: https://orcid.org/0000-0003-3233-6206)
Nan Zheng (ORCID: https://orcid.org/0000-0002-4475-3712)
Javier G. Blanco (ORCID: https://orcid.org/0000-0003-3887-0370)
Hongshan Li (ORCID: https://orcid.org/0000-0002-8792-2774)
Ritu Chadda